Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 2/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.38 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8281253 | 0.86 | GRIN2B (0.46) | IL2HPGDSP2RX7LTA4HBRD4 | |
| SCHEMBL18930006 | 0.84 | NPC1 (0.46) | IL2HPGDSP2RX7LTA4HBRD4 | |
| SCHEMBL1459892 | 0.79 | NPC1 (0.44) | IL2HPGDSP2RX7LTA4HBRD4 | |
| SCHEMBL4764672 | 0.79 | LTA4H (0.42) | IL2HPGDSP2RX7LTA4HBRD4 | |
| SCHEMBL10317579 | 0.79 | NPC1 (0.51) | IL2HPGDSP2RX7LTA4HBRD4 | |
| SCHEMBL1127714 | 0.79 | LTA4H (0.42) | IL2HPGDSP2RX7LTA4HBRD4 | |
| SCHEMBL6499200 | 0.79 | NPC1 (0.50) | IL2KMOHPGDSP2RX7LTA4H | |
| SCHEMBL29123211 | 0.79 | LTA4H (0.40) | IL2HPGDSP2RX7LTA4HBRD4 | |
| SCHEMBL27820773 | 0.79 | CYP17A1 (0.48) | P2RX7LTA4H | |
| SCHEMBL8226440 | 0.79 | HPGDS (0.41) | IL2HPGDSP2RX7LTA4HBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408760-A1 | THIOPHENYL SULFONAMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Bristol-Myers Squibb Company (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110071199-A1 | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-24 | — | — | US | disclosed |
| US-20110071199-A1 | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-24 | — | — | US | disclosed |
| US-20110071199-A1 | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-24 | — | — | US | disclosed |
| WO-2010107997-A1 | THIOPHENYL SULFONAMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010107997-A1 | THIOPHENYL SULFONAMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071199-A1 | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease | APP, PSEN1, PSEN2 | IL2 4055/4885KMO 3752/4885NISCH 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.